10-Q Filing

MERCK & CO., INC. CIK: 310158 Q3 2023

Filing Information

Form Type	10-Q
Accession Number	`0001628280-23-036717`
Period End Date	20230930
Filing Date	20231103
Fiscal Year	2023
Fiscal Period	Q3
XBRL Instance	mrk-20230930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 56 Cash Flow Statement 74 Comprehensive Income 24

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$85.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$72.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.94B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.15B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.69B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.45B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.61B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.98B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$168.00M	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$498.00M	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $85 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$10.39B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $85 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$9.45B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $3,151 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	`InventoryNet`	$6.13B	USD	Point-in-time
Inventories (excludes inventories of $3,151 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	`InventoryNet`	$5.91B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$6.66B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$31.95B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$35.72B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.31B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.01B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,446 in 2023 and $17,985 in 2022	`PropertyPlantAndEquipmentNet`	$22.53B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,446 in 2023 and $17,985 in 2022	`PropertyPlantAndEquipmentNet`	$21.42B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Goodwill	`Goodwill`	$21.18B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$19.20B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$20.27B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$9.53B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$10.56B	USD	Point-in-time
Total Assets	`Assets`	$106.73B	USD	Point-in-time
Total Assets	`Assets`	$109.16B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.95B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$887.00M	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.26B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.51B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.16B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.84B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.98B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.99B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.88B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.88B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$23.09B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$24.24B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$28.75B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$33.97B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.02B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.32B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$7.34B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.36B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.38B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$57.08B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$61.08B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.92B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.77B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$102.48B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$98.31B	USD	Point-in-time
Less treasury stock, at cost: 1,041,809,729 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$56.49B	USD	Point-in-time
Less treasury stock, at cost: 1,041,809,729 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$57.07B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$45.99B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$41.25B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$67.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$54.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.52B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$41.30B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$43.32B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$106.73B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$109.16B	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$45.45B	USD	3 Qtrs
Sales	`Revenues`	$14.96B	USD	1 Quarter
Sales	`Revenues`	$45.48B	USD	3 Qtrs
Sales	`Revenues`	$15.96B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$13.53B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$4.26B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$12.21B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$3.93B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.52B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.52B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.70B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.36B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$20.90B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$9.77B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.40B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.31B	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$344.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$126.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$288.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$94.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-429.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-1.58B	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-126.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-388.00M	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.34B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$11.38B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$41.55B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$32.52B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.58B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.94B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$12.93B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.62B	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$870.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$2.33B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$330.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.42B	USD	3 Qtrs
Net Income	`ProfitLoss`	$4.75B	USD	1 Quarter
Net Income	`ProfitLoss`	$3.25B	USD	1 Quarter
Net Income	`ProfitLoss`	$11.51B	USD	3 Qtrs
Net Income	`ProfitLoss`	$1.60B	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$12.00M	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$6.00M	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.25B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.75B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.59B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$11.50B	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$4.55	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.63	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.87	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.28	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.62	USD	3 Qtrs
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.28	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$4.53	USD	3 Qtrs
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.86	USD	1 Quarter

Cash Flow Statement 74 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$134.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$64.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$71.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Net income	`ProfitLoss`	$4.75B	USD	1 Quarter
Net income	`ProfitLoss`	$3.25B	USD	1 Quarter
Net income	`ProfitLoss`	$11.51B	USD	3 Qtrs
Net income	`ProfitLoss`	$1.60B	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$1.58B	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$1.62B	USD	3 Qtrs
Depreciation	`Depreciation`	$1.39B	USD	3 Qtrs
Depreciation	`Depreciation`	$1.33B	USD	3 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$13.00M	USD	3 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$910.00M	USD	3 Qtrs
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-33.00M	USD	1 Quarter
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-1.36B	USD	3 Qtrs
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$240.00M	USD	3 Qtrs
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-371.00M	USD	1 Quarter
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquisitionOtherThanThroughBusinessCombinationWriteOffAssetAcquisitionTwo`	-	USD	3 Qtrs
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquisitionOtherThanThroughBusinessCombinationWriteOffAssetAcquisitionTwo`	$10.22B	USD	3 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	3 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-968.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.26B	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$396.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$478.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$-1.17B	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$94.00M	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.35B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.44B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$14.66B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$12.76B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.87B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$3.24B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$704.00M	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$710.00M	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$1.49B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$709.00M	USD	3 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$10.71B	USD	3 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	3 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	3 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	3 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$121.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-149.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$15.00M	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-14.14B	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.21B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$5.94B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.75B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$2.25B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$953.00M	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.59B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.26B	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$119.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$119.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-172.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-325.00M	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.56B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-7.57B	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-163.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-776.00M	USD	3 Qtrs
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-4.10B	USD	3 Qtrs
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$3.11B	USD	3 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.28B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $64 and $134 at September 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $64 and $134 at September 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $64 and $134 at September 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.28B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $64 and $134 at September 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time

Comprehensive Income 24 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.25B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.75B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.59B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$11.50B	USD	3 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$171.00M	USD	3 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$584.00M	USD	3 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$159.00M	USD	1 Quarter
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$338.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$186.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-92.00M	USD	3 Qtrs
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$75.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-244.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-175.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-568.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-990.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-148.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-314.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-16.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-416.00M	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.83B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.73B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$11.19B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$1.44B	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.